Fast Electrode for Hand Amputation
Trial Summary
What is the purpose of this trial?
Our goal is to temporarily implant the following groups for 540 +/- 30 days: 1. Forearm FAST electrodes 1. Five human partial hand amputees (amputated at the level of the hand) with 2 FAST electrodes in the ulnar nerve and 2-5 FAST electrodes in the median nerve. 2. Five human hand and forearm amputees (amputated at the level of the forearm) with 2 FAST electrodes in the ulnar nerve and 2-5 FAST electrodes in the median nerve . 2. Arm FAST electrodes 1. Five human partial hand amputees (amputated at the level of the hand) with 2 FAST electrodes in the ulnar nerve and 2-5 FAST electrodes in the median nerve. 2. Five human hand and forearm amputees (amputated at the level of the forearm) with 2 FAST electrodes in the ulnar nerve and 2-5 FAST electrodes in the median nerve. 3. Five human hand, forearm and arm amputees (amputated at the level of the arm) with 2 FAST electrodes in the ulnar nerve and 2-5 FAST electrodes in the median nerve.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment DEFT, DExterous Hand Control Through Fascicular Targeting, for hand amputation?
The FAST-LIFE approach, which is part of the DEFT treatment, has shown effectiveness in providing control over a robotic hand and restoring sensory feedback in upper-limb amputees by targeting specific nerve areas. Additionally, a bioelectric neural interface using similar technology demonstrated high accuracy control of a prosthetic hand, suggesting that DEFT could offer precise and intuitive control for amputees.12345
Is the Fast Electrode for Hand Amputation generally safe for humans?
How does the DEFT treatment differ from other treatments for hand amputation?
The DEFT treatment is unique because it uses a specialized approach called FAST (Fascicle-Specific Targeting) with LIFE (Longitudinal Intrafascicular Electrodes) to directly interface with the nerves in the residual limb, allowing for precise control of a prosthetic hand and restoration of sensory feedback. This method provides a more natural and intuitive control compared to traditional prosthetics, which often rely on surface muscle signals and lack detailed sensory feedback.1251011
Research Team
Jonathan Cheng, MD
Principal Investigator
UT Southwestern Medical Center
Eligibility Criteria
This trial is for adults who have had a hand, forearm, or arm amputation and can manage their pain well. Participants must be able to sign consent, take part in all study activities including device implantation and removal, and communicate effectively in English without an interpreter.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-operative
Pre-operative imaging and diagnostic studies including MRI, x-ray, EMG/Nerve conduction studies, and psychological assessment
Implantation Surgery
Surgery to implant FAST electrodes in the ulnar and median nerves, followed by immediate post-operative care
Post-operative Care
Weekly outpatient care for 3 weeks following implantation surgery, including inspection and dressing changes of electrode leads
Experimental Data Collection
Human physiology experiments including motor and sensory assessments, conducted up to 6 times per month
Explantation Surgery
Surgery to remove implanted electrodes, followed by post-operative care
Follow-up
Participants are monitored for safety and effectiveness after explantation
Treatment Details
Interventions
- DEFT
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
Defense Advanced Research Projects Agency
Collaborator
University of Minnesota
Collaborator
Arizona State University
Collaborator
Nerves Incorporated, Inc.
Collaborator